Rectal cancer

No benefit for local excision over rectal excision

Organ preservation strategies (by use of local excision) following a good response to neoadjuvant chemotherapy are an attractive proposition for patients with rectal cancer. However, multicentre randomised trials providing evidence of the benefits of local excision over total mesorectal excision (TME) were previously absent. Now, in the GRECCAR 2 study, good clinical responders were randomized to receive either local excision (n = 74) or TME (n = 71). At 2 years after surgery, one or more adverse events from a composite primary outcome occurred in 56% of the local excision group and 48% of the TME group (OR 1.33, 95% CI 0.62–2.86, P = 0.43). As 26 patients from the local excision group had a completion TME that increased morbidity, local excision was not shown to be superior to TME in terms of morbidity and long-term function.

References

  1. 1

    Rullier, E. et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31056-5 (2017)

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. No benefit for local excision over rectal excision. Nat Rev Gastroenterol Hepatol 14, 450 (2017). https://doi.org/10.1038/nrgastro.2017.96

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing